Edward Lee Carter/LinkedIn

Jun 4, 2026, 13:45

Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:

“The First-Ever AHA/ACC Acute PE Guideline Is Here

The 2026 AHA/ACC multisociety guideline for acute PE is a landmark — endorsed by 10 societies.

Here’s what you need to know.

NEW: PE Categories A–E (Goodbye ‘Massive/Submassive’)

A new 5-category severity system integrating clinical scores, biomarkers, RV imaging, and hemodynamics:

A — Incidental/asymptomatic – May discharge from ED

B — Symptomatic, low severity (sPESI less than 1) – Early discharge

C — Elevated severity – Hospitalize; subcategories by biomarkers/RV dysfunction

D — Pre-cardiopulmonary failure – Close monitoring; advanced therapies considered

E — Cardiopulmonary failure/shock – Advanced intervention indicated

Anticoagulation highlights

DOACs over warfarin – comparable efficacy, lower bleeding (especially ICH)
LMWH over UFH – fewer recurrent VTE, lower HIT risk
Empiric anticoagulation reasonable if high pretest probability and low bleed risk
VKAs preferred for antiphospholipid syndrome
DOACs contraindicated in pregnancy/breastfeeding

Duration of anticoagulation

All patients: 3–6 months initial phase
Unprovoked PE: Extended anticoagulation (no planned stop) — approximately 30–40% recurrence at 10 yrs without it
Major reversible provocation (surgery): Safe to stop at 3–6 months

Other highlights

PERTs formally recommended – improve time-to-treatment, reduce IVC filter use

Follow-up within 48h–7 days; dedicated 3-month visit to reassess duration

Screen for CTEPD at every visit for greater than or equals to 1 year (complicates 2–4% of PEs)

PEERLESS (n equals 550): No mortality difference — mechanical thrombectomy vs. catheter-directed lysis

FLAME (n equals 115): MT showed 1.9% vs. 29.5% in-hospital mortality inhigh-risk PE

Bottom line

A clearer severity language, DOACs as first-line, stronger case for extended anticoagulation, and formal PERT endorsement.

Full guideline: Circulation and JACC, Feb 2026″